{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:31:28Z","timestamp":1792801888789,"version":"4.5.0"},"reference-count":32,"publisher":"Society of Nuclear Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2026,7,1]]},"DOI":"10.2967\/jnumed.126.272007","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:30:20Z","timestamp":1787243420000},"page":"jnumed.126.272007","source":"Crossref","is-referenced-by-count":1,"title":["Safety, Biodistribution, and Dosimetry of FAP and Integrin \u03b1\n                    <sub>v<\/sub>\n                    \u03b2\n                    <sub>3<\/sub>\n                    Dual-Targeting Radioligand\n                    <sup>177<\/sup>\n                    Lu-DOTA-FAPI-RGD: Preclinical Validation and First-in-Human Study in Patients with Advanced Adenocarcinomas"],"prefix":"10.2967","author":[{"given":"Jialin","family":"Xiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejun","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongxi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiarou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingtong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naixin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"2026082708000986000_jnumed.126.272007v2.1","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","article-title":"[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study","volume":"403","author":"Singh","year":"2024","journal-title":"The Lancet."},{"key":"2026082708000986000_jnumed.126.272007v2.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00237-3"},{"key":"2026082708000986000_jnumed.126.272007v2.3","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1186\/s12951-024-03020-3","article-title":"Radionuclide-labelled nanoparticles for cancer combination therapy: a review","volume":"22","author":"Sun","year":"2024","journal-title":"J Nanobiotechnol."},{"key":"2026082708000986000_jnumed.126.272007v2.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40850-5"},{"key":"2026082708000986000_jnumed.126.272007v2.5","doi-asserted-by":"crossref","first-page":"5744","DOI":"10.3390\/cancers13225744","article-title":"Radioligands targeting fibroblast activation protein (FAP)","volume":"13","author":"Lindner","year":"2021","journal-title":"Cancers (Basel)."},{"key":"2026082708000986000_jnumed.126.272007v2.6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1148\/radiol.2021204677","article-title":"Simultaneous FAPI PET\/MRI targeting the fibroblast-activation protein for breast cancer","volume":"302","author":"Backhaus","year":"2022","journal-title":"Radiology."},{"key":"2026082708000986000_jnumed.126.272007v2.7","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264827"},{"key":"2026082708000986000_jnumed.126.272007v2.8","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.267281"},{"key":"2026082708000986000_jnumed.126.272007v2.9","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.259192"},{"key":"2026082708000986000_jnumed.126.272007v2.10","first-page":"65","article-title":"Novel fibroblast activation protein inhibitor-based targeted theranostics for radioiodine-refractory differentiated thyroid cancer patients: a pilot study","volume":"32","author":"Ballal","year":"2022","journal-title":"Thyroid."},{"key":"2026082708000986000_jnumed.126.272007v2.11","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1097\/RLU.0000000000003810","article-title":"Feasibility and therapeutic potential of 177Lu-fibroblast activation protein inhibitor-46 for patients with relapsed or refractory cancers: a preliminary study","volume":"46","author":"Assadi","year":"2021","journal-title":"Clin Nucl Med."},{"key":"2026082708000986000_jnumed.126.272007v2.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2021.12.025"},{"key":"2026082708000986000_jnumed.126.272007v2.13","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13046-018-0694-6","article-title":"14, 15-EET induces breast cancer cell EMT and cisplatin resistance by up-regulating integrin \u03b1v\u03b23 and activating FAK\/PI3K\/AKT signaling","volume":"37","author":"Luo","year":"2018","journal-title":"J Exp Clin Cancer Res."},{"key":"2026082708000986000_jnumed.126.272007v2.14","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13045-020-01009-7","article-title":"Abnormally activated OPN\/integrin \u03b1V\u03b23\/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer","volume":"13","author":"Fu","year":"2020","journal-title":"J Hematol Oncol."},{"key":"2026082708000986000_jnumed.126.272007v2.15","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.3390\/ph17111556","article-title":"Integrin targeting and beyond: enhancing cancer treatment with dual-targeting RGD (arginine-glycine-aspartate) strategies","volume":"17","author":"Bogdanovi\u0107","year":"2024","journal-title":"Pharmaceuticals (Basel)."},{"key":"2026082708000986000_jnumed.126.272007v2.16","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.220749"},{"key":"2026082708000986000_jnumed.126.272007v2.17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.160648"},{"key":"2026082708000986000_jnumed.126.272007v2.18","doi-asserted-by":"crossref","first-page":"7180","DOI":"10.7150\/thno.79144","article-title":"Synthesis, preclinical evaluation and radiation dosimetry of a dual targeting PET tracer [68Ga]Ga-FAPI-RGD","volume":"12","author":"Zang","year":"2022","journal-title":"Theranostics."},{"key":"2026082708000986000_jnumed.126.272007v2.19","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.7150\/thno.86007","article-title":"Dual targeting PET tracer [68Ga]Ga-FAPI-RGD in patients with lung neoplasms: a pilot exploratory study","volume":"13","author":"Wang","year":"2023","journal-title":"Theranostics."},{"key":"2026082708000986000_jnumed.126.272007v2.20","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1158\/1078-0432.CCR-23-1983","article-title":"Fibroblast activation protein-targeted radioligand therapy with 177Lu-EB-FAPI for metastatic radioiodine-refractory thyroid cancer: first-in-human, dose-escalation study","volume":"29","author":"Fu","year":"2023","journal-title":"Clini Cancer Res."},{"key":"2026082708000986000_jnumed.126.272007v2.21","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264857"},{"key":"2026082708000986000_jnumed.126.272007v2.22","doi-asserted-by":"crossref","first-page":"6437","DOI":"10.7150\/thno.77219","article-title":"Safety and efficacy of peptide receptor radionuclide therapy with 177Lu-DOTA-EB-TATE in patients with metastatic neuroendocrine tumors","volume":"12","author":"Jiang","year":"2022","journal-title":"Theranostics."},{"key":"2026082708000986000_jnumed.126.272007v2.23","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1007\/s00259-025-07617-0","article-title":"Safety and efficacy of 177Lu-FAPI-XT radioligand therapy in patients with advanced sarcoma and other cancer entities: first-in-human, dose-escalation study","volume":"53","author":"Liu","year":"2026","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026082708000986000_jnumed.126.272007v2.24","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262468"},{"key":"2026082708000986000_jnumed.126.272007v2.25","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/RLU.0000000000003667","article-title":"Safety of fibroblast activation protein-targeted radionuclide therapy by a low-dose dosimetric approach using 177Lu-FAPI-04","volume":"46","author":"Kuyumcu","year":"2021","journal-title":"Clin Nucl Med."},{"key":"2026082708000986000_jnumed.126.272007v2.26","doi-asserted-by":"crossref","first-page":"17112","DOI":"10.1002\/cam4.6360","article-title":"Real-world treatment outcomes of medicines used in special situations (off-label and compassionate use) in oncology and hematology: a retrospective study from a comprehensive cancer institution","volume":"12","author":"Fontanals","year":"2023","journal-title":"Cancer Med."},{"key":"2026082708000986000_jnumed.126.272007v2.27","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.freeradbiomed.2019.11.007","article-title":"Mitochondrial dysfunction and oxidative stress in bone marrow stromal cells induced by daunorubicin leads to DNA damage in hematopoietic cells","volume":"146","author":"Li","year":"2020","journal-title":"Free Radic Biol Med."},{"key":"2026082708000986000_jnumed.126.272007v2.28","doi-asserted-by":"crossref","first-page":"3905216","DOI":"10.1155\/2017\/3905216","article-title":"Tumor burden and intraosseous metabolic activity as predictors of bone marrow failure during radioisotope therapy in metastasized prostate cancer patients","volume":"2017","author":"Fiz","year":"2017","journal-title":"Biomed Res Int."},{"key":"2026082708000986000_jnumed.126.272007v2.29","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14214"},{"key":"2026082708000986000_jnumed.126.272007v2.30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-335430"},{"key":"2026082708000986000_jnumed.126.272007v2.31","doi-asserted-by":"publisher","DOI":"10.2967\/jnmt.123.265668"},{"key":"2026082708000986000_jnumed.126.272007v2.32","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268386"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.126.272007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:00:20Z","timestamp":1787842820000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.126.272007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":32,"alternative-id":["10.2967\/jnumed.126.272007"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.126.272007","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]}}}